Release of our first CSR Report!
We’re excited to announce the publication of our first CSR Report!
The agreement between BMG Pharma and HTL will allow BMG Pharma to develop and commercialize injectable products with Sodium Hyaluronate Lipoate Formate (SHLF). BMG Pharma through its patented Hyaluromimethic® Technology works on SHLF to develop solutions in aesthetic dermatology, ophthalmology, and arthrosis.
– Thanks to this agreement, BMG Pharma will globally develop new formulations of its injectable products, always with high levels of quality, stability, and safety standards.
Read more below
As part of National Biomanufacturing Day 2025, HTL Biotechnology inaugurates a new production line dedicated to Hyaluronic Acid.
HTL Biotechnology is proud to support National Biomedicines manufacturing Day, which will take place on June 5, 2025.
HTL Biotechnology CEO François Fournier spoke to leading Korean media DongA Ilbo, reaffirming Korea’s strategic importance and the strong, long-standing ties with Korean customers.